Update: RSV vaccine for pregnant individuals and infants
Newborns are the highest risk individuals for severe outcomes related to RSV. There are two new publicly funded products in the 2024/25 respiratory season to protect newborns from RSV:
- Beyfortus: A monoclonal antibody product available for infants and high-risk children. It will be available in mid to late October.
- Abrysvo: A vaccine available for pregnant individuals (32-36 weeks) to protect newborns from RSV from birth until they are approximately six months of age.
The mother and the infant should not both receive a vaccine/product – it should be one or the other, unless meeting high risk criteria. Providing Beyfortus to the infant is the recommended approach for protection of the infant per the National Advisory Committee on Immunization (NACI), with the vaccine Abrysvo being available on a case-by-case basis to pregnant individuals.
NOTE: The RSV vaccine Arexvy SHOULD NOT be used in pregnant individuals.
Abysrvo is available now to order from HPEPH. Please use the High Risk Vaccine Order Form on our website. Please order minimally for your population considering the recommendations from NACI noted above.
Additional information about RSV vaccine for infants was provided in the Sept. 4 Public Health Bulletin.
Additional resources:
.png?1632837722057)
.png?1578593886679)